Manufacturers of opioid overdose reversal drugs, including several generics firms, intend produce an additional 25m doses of their products in the US following a meeting with the White House Office of National Drug Control Policy.
Hosted by ONDCP director Rahul Gupta and White House Domestic Policy Council advisor Neera Tanden, the meeting on 4 June...







